Health and Healthcare
Implant Maker ConforMIS Jumps a Third on IPO
Published:
Last Updated:
Joint bookrunners for the offering are JPMorgan and Deutsche Bank. Co-managers are Wells Fargo Securities, Canaccord Genuity and Oppenheimer. The underwriters have a 30-day option to purchase an additional 1.35 million shares.
ConforMIS is a medical technology company that uses a proprietary technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped to fit each patient’s anatomy.
The technology includes the use of 3D printing to manufacture what ConforMIS calls iJig Instrumentations, a precise set of sterilized, disposable surgical instruments that come with each implant. ConforMIS claims that this reduces the number of instruments required for an implant and also reduces the steps in the surgical technique.
The company estimates the global market for joint replacement products is $15 billion and reported $48.2 million in revenue for 2014 and $14.7 million for the first quarter of 2015.
ALSO READ: 6 Stocks Analysts Predict Will Double
At the $15 per share IPO price, the company raised net proceeds of about $121 million, which it plans to use in the following ways:
At the end of the noon hour on Wednesday, the stock traded at $18.93, up about 26% above the IPO price.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.